Vaginal Microbiome Seeding and Health Outcomes in Cesarean-delivered Neonates.
NCT03298334
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
Neonates delivered by scheduled Cesarean Section will be randomized to receive vaginal seeding (exposing the infant to Mother's vaginal flora) or sham. Infants will be followed for three years to examine health outcomes including microbiome development, immune development, metabolic outcomes, and any adverse events.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Cesarean Delivery Affecting Newborn
- Obesity, Childhood
- Intestinal Microbiome
- Microbiota
- Host Microbial Interactions
- Gastrointestinal Microbiome
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 0 days to 50 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Last updated on ClinicalTrials.gov
- June 8, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Virginia · 1
- Inova Health System · Falls Church, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.